Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
FedEx Corporation ( FDX - Analyst Report ) has closed the TATEX Express buyout, which was proposed in April. French-based TATEX Express provides courier and express transport services to industrial customers across Europe and international markets.
Although the terms of the deal remain undisclosed, we expect FedEx to gain from the proven market position of TATEX. Annual shipments of TATEX come to 19 million parcels, accounting for 150 million Euros in sales revenue.
Additionally, FedEx recently wrapped up its acquisition of Brazilian transport and logistics company, Rapidao Cometa. With $500 million annual revenues (as of 2011), 770 vehicles and 145 distribution centers, Rapidao Cometa remains a strategic fit for FedEx to strengthen its Brazilian footprint and is concurrent with its plan to expand in Latin America and the Caribbean markets.
We believe that the acquisition strategy of FedEx remains impressive as these takeovers will enable the company to spread in a variety of target markets. We foresee potential opportunities not only in Europe but also in emerging markets like China, India, Japan and Brazil, as well as other Asian regions for international growth.
Prior to these acquisitions, FedEx acquired Polish company, Opek Sp.z o.o, which is estimated to garner annual revenue and shipments of $70 million and 12.5 million, respectively.
However, it is difficult to quantify the near-term financial gains that the company will derive out of its recent expansion initiatives, particularly in Europe, where sovereign debt concerns could significantly weigh on the economic recovery. Moreover, the company faces stiff competition from United Parcel Service ( UPS - Analyst Report ) . However, long-term prospects of these acquisitions look promising.
Currently, FedEx retains a Zacks #3 Rank (short-term Hold recommendation). We also reiterate our long-term Neutral rating on the stock.
Read the full reports :
Analyst Report on FDX
Analyst Report on UPS